Monopar Therapeutics (NASDAQ:MNPR) Posts Earnings Results

Monopar Therapeutics (NASDAQ:MNPR) released its quarterly earnings results on Thursday. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02), Zacks reports.

Monopar Therapeutics Trading Down 10.4%

Shares of NASDAQ MNPR traded down $9.01 during mid-day trading on Friday, reaching $78.00. The company had a trading volume of 273,303 shares, compared to its average volume of 137,479. The company has a 50-day moving average price of $78.12 and a two-hundred day moving average price of $51.42. The stock has a market cap of $481.26 million, a PE ratio of -22.67 and a beta of 1.35. Monopar Therapeutics has a 1-year low of $17.09 and a 1-year high of $105.00.

Insider Activity at Monopar Therapeutics

In related news, major shareholder Tactic Pharma Llc sold 550,229 shares of the stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total value of $35,000,066.69. Following the completion of the transaction, the insider owned 272,026 shares in the company, valued at $17,303,573.86. This trade represents a 66.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 20.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Monopar Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. acquired a new position in shares of Monopar Therapeutics in the first quarter worth about $673,000. Jane Street Group LLC purchased a new stake in shares of Monopar Therapeutics in the 1st quarter valued at approximately $377,000. Geode Capital Management LLC boosted its stake in Monopar Therapeutics by 99.7% in the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock worth $3,468,000 after purchasing an additional 48,379 shares during the period. JPMorgan Chase & Co. grew its position in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after purchasing an additional 1,821 shares in the last quarter. Finally, Rhumbline Advisers purchased a new position in Monopar Therapeutics during the 2nd quarter worth approximately $209,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Analyst Upgrades and Downgrades

MNPR has been the topic of a number of research analyst reports. Oppenheimer set a $115.00 price objective on shares of Monopar Therapeutics and gave the company an “outperform” rating in a research note on Thursday, October 2nd. Piper Sandler set a $95.00 price target on Monopar Therapeutics and gave the company an “overweight” rating in a research note on Thursday, September 25th. HC Wainwright set a $105.00 price objective on Monopar Therapeutics and gave the stock a “buy” rating in a research note on Monday, September 29th. Leerink Partners began coverage on Monopar Therapeutics in a report on Monday, November 10th. They issued an “outperform” rating and a $115.00 price objective for the company. Finally, Leerink Partnrs raised Monopar Therapeutics to a “strong-buy” rating in a research note on Monday, November 10th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $106.20.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.